Replies to post #30804 on Marker Therapeutics Inc (MRKR)

[Lady_luck]

I believe these are the same

T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects
https://ascopubs.org/doi/full/10.1200/JCO.20.02224

For what ever reason there has been no press release. This is very very positive news.... if this was a different company, we probably would have been well north of $10 by now in anticipation of the news, then way up from there to $20’s... but very little following here.

TACTAL – Leukemia: NCT01333046
https://clinicaltrials.gov/ct2/show/NCT01333046?term=multitaa&rank=4